Deng Min, Wu Shuang, Huang Peizheng, Liu Yun, Li Chong, Zheng Ji
Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing 400037, China.
Medical Research Institute, Southwest University, Chongqing 400716, China.
Asian J Pharm Sci. 2023 Nov;18(6):100870. doi: 10.1016/j.ajps.2023.100870. Epub 2023 Nov 29.
Metastasis-associated processes are the predominant instigator of fatalities linked to cancer, wherein the pivotal role of circulating tumor cells lies in the resurgence of malignant growth. In recent epochs, exosomes, constituents of the extracellular vesicle cohort, have garnered attention within the field of tumor theranostics owing to their inherent attributes encompassing biocompatibility, modifiability, payload capacity, stability, and therapeutic suitability. Nonetheless, the rudimentary functionalities and limited efficacy of unmodified exosomes curtail their prospective utility. In an effort to surmount these shortcomings, intricate methodologies amalgamating nanotechnology with genetic manipulation, chemotherapy, immunotherapy, and optical intervention present themselves as enhanced avenues to surveil and intercede in tumor metastasis and relapse. This review delves into the manifold techniques currently employed to engineer exosomes, with a specific focus on elucidating the interplay between exosomes and the metastatic cascade, alongside the implementation of tailored exosomes in abating tumor metastasis and recurrence. This review not only advances comprehension of the evolving landscape within this domain but also steers the trajectory of forthcoming investigations.
转移相关过程是癌症相关死亡的主要诱因,其中循环肿瘤细胞的关键作用在于恶性肿瘤的复发。近年来,作为细胞外囊泡群体成分的外泌体,因其具有生物相容性、可修饰性、有效载荷能力、稳定性和治疗适用性等固有特性,在肿瘤诊疗领域受到了关注。然而,未修饰外泌体的基本功能和有限疗效限制了它们的潜在应用。为了克服这些缺点,将纳米技术与基因操作、化疗、免疫治疗和光学干预相结合的复杂方法成为监测和干预肿瘤转移及复发的更好途径。本文综述了目前用于工程化外泌体的多种技术,特别关注阐明外泌体与转移级联之间的相互作用,以及定制外泌体在减轻肿瘤转移和复发方面的应用。这篇综述不仅增进了对该领域不断变化的格局的理解,还为未来的研究指明了方向。
Asian J Pharm Sci. 2023-11
ACS Biomater Sci Eng. 2023-10-9
J Transl Med. 2021-7-19
ACS Appl Bio Mater. 2023-7-17
Cell Oncol (Dordr). 2018-4-17
Front Bioeng Biotechnol. 2023-11-14
Crit Rev Biotechnol. 2020-9
Front Immunol. 2025-5-29
Pharmaceutics. 2025-2-5
Int J Nanomedicine. 2024
J Nanobiotechnology. 2023-9-16
Mater Today Bio. 2023-8-11
Pharmaceutics. 2023-5-14
Mil Med Res. 2023-4-28
Signal Transduct Target Ther. 2023-3-15